MedTrace Logo

Dexmedetomidine for Prophylaxis Against PONV in Highly Susceptible Patients.

NCT05134363 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2023-08-30

No results posted yet for this study

Summary

The study aims to compare between two bolus doses of dexmedetomidine in preventing PONV in highly susceptible patients.

Conditions

  • Postoperative Nausea and Vomiting
  • Head and Neck Surgeries

Interventions

DRUG

Dexmedetomidine Hydrochloride 0.5 mic/kg bolus

comparison between two bolus doses of dexmedetomidine with a placebo group

DRUG

Dexmedetomidine Hydrochloride 0.75 mic/kg bolus

comparison between two bolus doses of dexmedetomidine with a conventional group receiving ondansetron.

DRUG

Placebo

equal volume of normal saline

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2023-06-20
Completion
2023-06-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05134363 on ClinicalTrials.gov